Peptide News Digest

#Rare-Obesity-Disorders

1 story

Research · View digest

Palatin Picks PL2001, a Long-Acting MC4R Peptide Built to Avoid Skin Darkening, for Rare Obesity Disorders

At ObesityWeek, Palatin Technologies presented animal and cell data on lipidated peptides that activate the MC4R appetite receptor while showing minimal to no activity at MC1R, the receptor behind the skin darkening seen with current MC4R drugs. The company said they reduced body weight and food intake in preclinical models. It has chosen PL2001 for development in hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, with first human studies targeted for the first half of 2027.